ArticleThe Journal of clinical investigation2021
Genetic blockade of lymphangiogenesis does not impair cardiac function after myocardial infarction.
Article in The Journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 52 citations in OpenAlex.
- Cardiac lymphatic dysfunction and repair in cardiovascular disease.Nature reviews. Cardiology · 2026Review
- Age-associated loss of lymphatic vessels promotes cardiac inflammation.Nature cardiovascular research · 2026Article
- Lymphatic Endothelial Cells in Health and Disease.MedComm · 2026Review
- Cardiac Lymphatic Dysfunction in Heart Failure: A New Paradigm for Congestion, Inflammation, and Therapy.Medical sciences (Basel, Switzerland) · 2026Review
- Cardiac lymphatics retain LYVE-1-dependent macrophages during neonatal mouse heart regeneration.Nature cardiovascular research · 2025Article
- Artery formation in the intestinal wall and mesentery by intestine-derived Esm1+ endothelial cells.Nature communications · 2025Article
- Tissue-Engineered Therapeutics for Lymphatic Regeneration: Solutions for Myocardial Infarction and Secondary Lymphedema.Advanced healthcare materials · 2025Review
- The role of cardiac lymphatic dysfunction in the progression of myocarditis.Frontiers in cardiovascular medicine · 2025Review
- Differential vegfc expression dictates lymphatic response during zebrafish heart development and regeneration.Development (Cambridge, England) · 2024Article
- Heart regeneration from the whole-organism perspective to single-cell resolution.NPJ Regenerative medicine · 2024Review
- Lymphatic System Development and Function.Current cardiology reports · 2024Review
- Influenza induces lung lymphangiogenesis independent of YAP/TAZ activity in lymphatic endothelial cells.Scientific reports · 2024Article
- Sodium, Interstitium, Lymphatics and Hypertension-A Tale of Hydraulics.Hypertension (Dallas, Tex. : 1979) · 2024Review
- Influenza Induces Lung Lymphangiogenesis Independent of YAP/TAZ Activity in Lymphatic Endothelial Cells.Research square · 2024Article
- Mechanisms of Myocardial Edema Development in CVD Pathophysiology.Biomedicines · 2024Review
- Targeting lymphatic function in cardiovascular-kidney-metabolic syndrome: preclinical methods to analyze lymphatic function and therapeutic opportunities.Frontiers in cardiovascular medicine · 2024Review
- The emerging importance of lymphatics in health and disease: an NIH workshop report.The Journal of clinical investigation · 2023Review
- Mechanisms regulating vascular and lymphatic regeneration in the heart after myocardial infarction.The Journal of pathology · 2023Review
- VEGFR3 is required for button junction formation in lymphatic vessels.Cell reports · 2023Article
- Research progress in the cardiac lymphatic system and myocardial repair after myocardial infarction.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
Corrections and comments
- Commented on by
Authors and funding
13 authors at 3 institutions in 3 countries.
Funding
Abstract
In recent decades, treatments for myocardial infarction (MI), such as stem and progenitor cell therapy, have attracted considerable scientific and clinical attention but failed to improve patient outcomes. These efforts indicate that more rigorous mechanistic and functional testing of potential MI therapies is required. Recent studies have suggested that augmenting post-MI lymphatic growth via VEGF-C administration improves cardiac function. However, the mechanisms underlying this proposed therapeutic approach remain vague and untested. To more rigorously test the role of lymphatic vessel growth after MI, we examined the post-MI cardiac function of mice in which lymphangiogenesis had been blocked genetically by pan-endothelial or lymphatic endothelial loss of the lymphangiogenic receptor VEGFR3 or global loss of the VEGF-C and VEGF-D ligands. The results obtained using all 3 genetic approaches were highly concordant and demonstrated that loss of lymphatic vessel growth did not impair left ventricular ejection fraction 2 weeks after MI in mice. We observed a trend toward excess fluid in the infarcted region of the left ventricle, but immune cell infiltration and clearance were unchanged with loss of expanded lymphatics. These studies refute the hypothesis that lymphangiogenesis contributes significantly to cardiac function after MI, and suggest that any effect of exogenous VEGF-C is likely to be mediated by nonlymphangiogenic mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.